Search the Newsreel

Qiagen N.V. $QGEN Shares Sold by Edgestream Partners L.P.

Qiagen (QGEN) Stock Could Be A Cash Flow Bargain Yet Fair On Earnings

Qiagen NV (QGEN.BRN) Q4 2024 Earnings Report - Results, Call & Slides

Qiagen NV (QGEN.BRN) reported its Q4 2024 earnings, missing the consensus EPS estimate by -CHF0.01 with an actual EPS of CHF0.52. However, the company beat revenue expectations, reporting CHF424.78M against an expected CHF424.66M, marking a 2.36% year-over-year revenue growth. The earnings call and slide …

QGEN|Qiagen NV|Price:41.435|Chg%:-0.375

This article provides a detailed analysis of Qiagen NV (QGEN) stock, highlighting its current market trends, real-time quotes, and related analysis. It covers key financial figures, insights into its growth potential and valuation, and analyst ratings, which currently lean towards "Buy." The company's strengths …

Amundi Has $190.50 Million Stake in Qiagen N.V. $QGEN

Amundi increased its stake in Qiagen N.V. by 12.4% in the first quarter, now holding 4.76 million shares valued at $190.5 million, representing 2.31% of the company.

PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG

This article announces that QIAGEN N.V. has published a voting rights notification in accordance with § 40 Abs. 1 WpHG, as informed by the AFM on July 29, 2026. The notification details various share and voting rights distributions related to Goldman Sachs Group Inc., …

QIAGEN Number of Employees 2026 | Employee Count & Headcount Data

QIAGEN NV (QGEN) has approximately 5,617 employees worldwide as of March 2026, marking a 6.6% decline from 2023. The company is actively hiring, with 272 job postings in 2026, though new postings per month have decreased. The workforce is primarily concentrated in the United …

Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network

Stockholm-based service provider adds Evercode to its single cell sequencing offerings SEATTLE, July 29, 2026--(BUSINESS WIRE)--Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, …

Qiagen NV (QGEN) Institutional Confidence

Qiagen NV (QGEN) has an institutional shareholding score of 7.00, placing it 80th out of 385 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.32%, a 4.59% increase quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 980.90K shares, representing …

Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for

Analysts expect Qiagen (QGEN) to report a year-over-year decline in earnings and lower revenues for the quarter ended June 2026, with an expected earnings report date of August 5. The Zacks Earnings ESP for Qiagen is negative (-0.28%) and combined with a Zacks Rank …

Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday

Qiagen NV (QGEN) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Qiagen NV (QGEN)'s financial health, indicating a stable financial status and high operating efficiency with a current financial score of 8.79. The company reported a 1.83% year-over-year increase in quarterly revenue, reaching 492.32M, and a 25.03% year-over-year increase …

Is Qiagen (QGEN) A Bargain On Its Infectious Disease Testing Push?

Qiagen (QGEN) is focusing on infectious disease diagnostics, highlighted by its role in the U.S. cyclosporiasis response and the launch of a new CE-IVDR-certified panel. While the stock has seen a 21.6% return over the last 90 days, its year-to-date and one-year returns are …

Qiagen NV (QGEN) Cash Flow

This article provides a detailed cash flow statement for Qiagen NV (QGEN), covering quarterly and annual data for operating, investing, and financing activities. It also includes key financial metrics such as market cap, P/E ratio, and free cash flow. The report highlights Qiagen NV's …

Troluce Capital Advisors LLC Purchases Shares of 362,500 Qiagen N.V. $QGEN

Troluce Capital Advisors LLC newly acquired 362,500 shares of Qiagen N.V. (NYSE:QGEN) in the first quarter, valued at approximately $14.5 million, making Qiagen its 28th-largest holding and representing 0.18% of Qiagen's stock. Other institutional investors also adjusted their positions, and collectively, institutional investors own …

Sona Asset Management US LLC Invests $8.89 Million in Qiagen N.V. $QGEN

Sona Asset Management US LLC has acquired 222,060 shares of Qiagen N.V. (QGEN) worth $8.89 million, representing a 0.11% stake. Institutional investors collectively own approximately 70% of Qiagen. The company recently reported earnings of $0.54 per share, matching estimates, and increased its annual dividend …

Qiagen NV (QGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Qiagen NV (QGEN), categorizing its income by business segments and geographical regions. It highlights that "Consumables and Related Revenues" constitute the vast majority of its business, and the United States is its largest regional market. The …

UBS Group discloses 2.98% stake in QIAGEN via AFM filing

UBS Group AG has disclosed a 2.98% stake in QIAGEN, held through a combination of ordinary shares, options, swaps, and convertible bonds, according to a notification from the Dutch financial markets regulator AFM. This significant institutional holding highlights investor interest in QIAGEN stock, potentially …

BlackRock Discloses Significant Stake in Qiagen

BlackRock, Inc. and its affiliates have disclosed a substantial stake in Qiagen N.V., totaling 11.66% capital interest and 13.10% voting rights, through ordinary shares and contracts for difference. This significant holding by a global asset manager is expected to influence Qiagen's shareholder structure and …

Qiagen stock trades steady as diagnostics demand supports revenue growth

Qiagen stock shows stable demand for molecular diagnostics, with recent quarterly reports indicating mid-single-digit revenue growth and solid margins despite a challenging life-sciences market. The company focuses on base business growth, recurring revenue streams, and strategic investments in R&D and acquisitions to maintain its …

Bessemer Group Inc. Sells 43,977 Shares of Qiagen N.V. $QGEN

Bessemer Group Inc. significantly reduced its stake in Qiagen N.V. (NYSE:QGEN) by 84.4% in the first quarter, selling 43,977 shares and bringing its total holdings to 8,112 shares worth $324,000. Despite this, several other institutional investors increased their positions in Qiagen, and the company …

BlackRock builds 11.6% stake in Qiagen, lifting voting power to 13%

BlackRock, Inc. has increased its stake in Qiagen to an overall capital interest of 11.61% and voting rights of 13.04%, according to a filing with the Dutch Authority for the Financial Markets. This significant move by one of the world's largest asset managers underscores …

Does Qiagen's Expanded QIAstat-Dx Infection and AMR Menu Reframe the Bull Case for QGEN?

Qiagen recently expanded its QIAstat-Dx platform with new molecular testing capabilities for Cyclospora and a CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe. These advancements highlight Qiagen's strategy to position QIAstat-Dx as a comprehensive diagnostic tool for infectious diseases and antimicrobial resistance. While …

Qiagen stock trades steadily as molecular diagnostics growth supports margins

Qiagen N.V. (NL0012169213) demonstrates steady stock performance, driven by robust molecular diagnostics demand and efficient cost control. The company's financial health is underpinned by over $2 billion in annual revenue, resilient margins in the mid-to-high twenties percent range, and strong cash flow, which supports …

Capula Management Ltd Purchases New Stake in Qiagen N.V. $QGEN

Capula Management Ltd has acquired a new stake in Qiagen N.V. (NYSE:QGEN) during the first quarter, purchasing 27,820 shares valued at approximately $1,114,000. This comes as other institutional investors like Allspring Global Investments Holdings LLC and Vanguard Group Inc. have also adjusted their holdings …

Qiagen N.V. $QGEN Shares Acquired by Swiss National Bank

The Swiss National Bank significantly increased its holdings in Qiagen N.V. (NYSE:QGEN) by 21.1% in the first quarter, acquiring an additional 124,920 shares. This move is part of broader institutional interest, with several other hedge funds also adjusting their positions in the biotech company. …

Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN

Hsbc Holdings PLC recently acquired a new stake of 322,819 shares in Qiagen N.V., valued at approximately $12.92 million, representing 0.16% of the company. Other institutional investors have also adjusted their holdings in Qiagen, which has received a consensus "Hold" rating from analysts with …

KKR (KKR) After Qiagen Interest And Allyntra Launch Has Valuation Back In Focus

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. KKR stock in focus after Qiagen interest and medtech platform launch KKR (KKR) is back in the spotlight after reports linked the firm to …

KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. KKR (NYSE:KKR) has launched Allyntra, a precision-engineered solutions platform focused on advanced surgical technologies in medical technology. The company is pursuing a controlling stake …

Qiagen stock trades steady as diagnostics demand supports recent earnings

Qiagen's stock is trading steadily following strong Q1 2026 results, which saw revenue increase to $560 million from $510 million the previous year, and adjusted EPS rise to $0.50 from $0.45. The company's performance was driven by consistent demand for molecular diagnostics and life …

William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating

William Blair analyst Matt Larew has initiated coverage on Qiagen NV (QGEN.US) with a 'Hold' rating. Larew has a 54.8% success rate and a 10.1% average return over the past year, according to TipRanks data. The rating reflects an independent third-party analysis and is …

BlackRock Builds Significant Stake in Qiagen, Boosting Institutional Presence

BlackRock, Inc. has significantly increased its stake in Qiagen N.V., now holding a combined capital interest of 12.19% and voting rights of 13.64%. This move, disclosed by the Netherlands Authority for the Financial Markets, highlights growing institutional interest in Qiagen and is expected to …

Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN

Allspring Global Investments Holdings LLC reduced its stake in Qiagen N.V. (NYSE:QGEN) by 21.6% in Q1 2026, valuing its remaining position at $100.21 million. Other institutional investors like Danske Bank A S and Manchester Capital Management LLC also adjusted their holdings. Qiagen recently announced …

Qiagen (QGEN) Investor presentation Summary

Qiagen (QGEN) reported Q1 2026 net sales of $492 million, up 2% actual but down 1% at constant exchange rates (CER), with adjusted diluted EPS at $0.54, meeting expectations. Sample technologies and QIAcuity showed strong growth, while QuantiFERON sales declined due to lower immigration …

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN is providing molecular testing solutions to support the public health response to a growing Cyclospora outbreak in the U.S., with over 1,600 confirmed cases since May 2026. Their FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour. Additionally, QIAGEN …

Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak

QIAGEN N.V. announced its molecular testing solutions are available to support the U.S. public health response to a recent cyclosporiasis outbreak, which has over 1,600 confirmed cases. The company's QIAstat-Dx Gastrointestinal Panel 2 can detect the parasite, Cyclospora cayetanensis, in about an hour, addressing …